Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)Zhengyang Yang, Zhongtao Zhang, Zhigang Bai et al.|BMC Cancer|2022Cited by 26
Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancerJiale Gao, Zhongtao Zhang, Xiao Zhang et al.|Frontiers in Oncology|2023Cited by 21